Enanta Pharmaceuticals Inc (ENTA) : Krensavage Asset Management scooped up 4,083 additional shares in Enanta Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 882,529 shares of Enanta Pharmaceuticals Inc which is valued at $21.7 Million.Enanta Pharmaceuticals Inc makes up approximately 7.94% of Krensavage Asset Management’s portfolio.
Other Hedge Funds, Including , Alliancebernstein boosted its stake in ENTA in the latest quarter, The investment management firm added 4,710 additional shares and now holds a total of 28,750 shares of Enanta Pharmaceuticals Inc which is valued at $706,388. Lsv Asset Management sold out all of its stake in ENTA during the most recent quarter. The investment firm sold 72,200 shares of ENTA which is valued $1.8 Million.Schroder Investment Management Group reduced its stake in ENTA by selling 397,487 shares or 90.48% in the most recent quarter. The Hedge Fund company now holds 41,816 shares of ENTA which is valued at $1 Million.New York State Common Retirement Fund boosted its stake in ENTA in the latest quarter, The investment management firm added 7,281 additional shares and now holds a total of 140,850 shares of Enanta Pharmaceuticals Inc which is valued at $3.5 Million. Enanta Pharmaceuticals Inc makes up approx 0.01% of New York State Common Retirement Fund’s portfolio.Tiaa Cref Investment Management reduced its stake in ENTA by selling 9,589 shares or 14.19% in the most recent quarter. The Hedge Fund company now holds 58,008 shares of ENTA which is valued at $1.4 Million.
Enanta Pharmaceuticals Inc closed down -0.45 points or -1.86% at $23.79 with 2,24,095 shares getting traded on Wednesday. Post opening the session at $24.27, the shares hit an intraday low of $23.59 and an intraday high of $24.56 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Enanta Pharmaceuticals Inc reported $-0.09 EPS for the quarter, missing the analyst consensus estimate by $ -0.19 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $0.10. The company had revenue of $13.00 million for the quarter, compared to analysts expectations of $16.80 million. The company’s revenue was down -77.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.49 EPS.
Many Wall Street Analysts have commented on Enanta Pharmaceuticals Inc. Enanta Pharmaceuticals Inc was Downgraded by JMP Securities to ” Mkt Perform” on Apr 28, 2016.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.